Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients With COPD
July 04, 2024
July 04, 2024
PARIS, France, July 4 -- Sanofi, a life sciences company, issued the following news release:
* * *
* First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
* Dupixent is the first new treatment approach for COPD in more than a decade and a new option f . . .
* * *
* First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
* Dupixent is the first new treatment approach for COPD in more than a decade and a new option f . . .